However, the opportunity to conduct a study in Eastern Europe has led to the decision to carve out the
dose-escalation and dose-expansion arms of the proposed U.S. study in order to generate the all-
important safety and early proof-of-principle efficacy data (based on biomarkers and clinical signals) in
what the Company believes will be a far more timely and cost-effective manner than would have been
possible in the U.S. The Company anticipates that it should be possible to commence a trial in Eastern
Europe an estimated 4-5 months earlier than in the U.S.; per patient costs in the U.S. are estimated at 4-
5 times that in Eastern Europe.
- Forums
- ASX - By Stock
- Ann: COVID-19 Trial Program to Commence in Europe
However, the opportunity to conduct a study in Eastern Europe...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NOX (ASX) to my watchlist
(20min delay)
|
|||||
Last
6.7¢ |
Change
0.001(1.52%) |
Mkt cap ! $19.57M |
Open | High | Low | Value | Volume |
6.7¢ | 6.7¢ | 6.7¢ | $818 | 12.21K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 17790 | 6.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.0¢ | 4049 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 17790 | 0.067 |
1 | 24715 | 0.066 |
1 | 15000 | 0.065 |
1 | 10000 | 0.064 |
1 | 100000 | 0.062 |
Price($) | Vol. | No. |
---|---|---|
0.070 | 4049 | 1 |
0.079 | 11999 | 1 |
0.080 | 12099 | 2 |
0.081 | 22345 | 2 |
0.090 | 52000 | 3 |
Last trade - 15.44pm 12/07/2024 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |